Lantern Pharma, Inc. (LTRN)

2.71 +0.22 (+8.84%) USD  |  NASDAQ  |  Apr 20, 12:56
More

Lantern Pharma SG&A Expense (Quarterly) : 1.458M for Dec. 31, 2025

SG&A Expense (Quarterly) Chart

View SG&A Expense (Quarterly) for LTRN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense (Quarterly) Range, Past 5 Years

View SG&A Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (Quarterly) Benchmarks

View SG&A Expense (Quarterly) Benchmarks
Start Trial
Vertex Pharmaceuticals, Inc. 487.00M
BioVie, Inc. 1.936M
Acurx Pharmaceuticals, Inc. 1.335M
ACADIA Pharmaceuticals, Inc. 155.62M
Alnylam Pharmaceuticals, Inc. 325.37M